Refine
Year of publication
Language
- English (896)
Has Fulltext
- yes (896)
Is part of the Bibliography
- no (896)
Keywords
- Heavy Ion Experiments (18)
- Hadron-Hadron scattering (experiments) (11)
- Hadron-Hadron Scattering (10)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- ALICE (3)
- Heavy Ions (3)
- Heavy Quark Production (3)
- pp collisions (3)
- Beauty production (2)
- COVID-19 (2)
- Charm physics (2)
- Diffraction (2)
- Elastic scattering (2)
- Elliptic flow (2)
- Heavy-ion collisions (2)
- Jets and Jet Substructure (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- Quark-Gluon Plasma (2)
- Quarkonium (2)
- Single electrons (2)
- 900 GeV (1)
- AICAR (1)
- ALICE detector (1)
- AMPK (1)
- Advanced stage (1)
- Anti-nuclei (1)
- B-slope (1)
- Biodiversity (1)
- Boosted Jets (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Coalescence (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Collectivity (1)
- Comparison with QCD (1)
- Complicated stage (1)
- Conservation biology (1)
- Correlation (1)
- Critical point (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Environmental impact (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Groomed jet radius (1)
- HBT (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Higher moments (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- LEOSS (1)
- Lepton-Nucleon Scattering (experiments) (1)
- Machine learning (1)
- Material budget (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiple parton interactions (1)
- Neural network (1)
- Nuclear modification factor (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Predictive model (1)
- Production Cross Section (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- RHIC (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Resolution Parameter (1)
- SARS-CoV-2 (1)
- Shear viscosity (1)
- Single muons (1)
- SoftDrop (1)
- Splitting function (1)
- Systematic Uncertainty (1)
- TR (1)
- Thermal model (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Transversity (1)
- Trigger (1)
- Vector Boson Production (1)
- Xenon-based gas mixture (1)
- advanced melanoma (1)
- comorbidities (1)
- complete response (1)
- critically ill patients (1)
- cytokines (1)
- dE/dx (1)
- detector (1)
- discontinuation (1)
- disease progression (1)
- experimental results (1)
- heavy ion experiments (1)
- inflammation (1)
- lasso regression (1)
- macrophage (1)
- metformin (1)
- nomogram (1)
- p+p collisions (1)
- quark gluon plasma (1)
- risk factors (1)
- second-line immunotherapy (1)
- spectra (1)
- targeted therapy (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (860)
- Frankfurt Institute for Advanced Studies (FIAS) (819)
- Informatik (769)
- Medizin (8)
- Hochschulrechenzentrum (2)
- Institut für Ökologie, Evolution und Diversität (1)
Measurement of inclusive J/ψ polarization in p + p collisions at √s=200 GeV by the STAR experiment
(2020)
We report on new measurements of inclusive 𝐽/𝜓 polarization at midrapidity in 𝑝+𝑝 collisions at √𝑠=200 GeV by the STAR experiment at the Relativistic Heavy Ion Collider. The polarization parameters, 𝜆𝜃, 𝜆𝜙, and 𝜆𝜃𝜙, are measured as a function of transverse momentum (𝑝T) in both the helicity and Collins-Soper (CS) reference frames within 𝑝T<10 GeV/𝑐. Except for 𝜆𝜃 in the CS frame at the highest measured 𝑝T, all three polarization parameters are consistent with 0 in both reference frames without any strong 𝑝T dependence. Several model calculations are compared with data, and the one using the Color Glass Condensate effective field theory coupled with nonrelativistic QCD gives the best overall description of the experimental results, even though other models cannot be ruled out due to experimental uncertainties.
Elliptic flow measurements from two-, four- and six-particle correlations are used to investigate flow fluctuations in collisions of U+U at sNN−−−√= 193 GeV, Cu+Au at sNN−−−√= 200 GeV and Au+Au spanning the range sNN−−−√= 11.5 - 200 GeV. The measurements show a strong dependence of the flow fluctuations on collision centrality, a modest dependence on system size, and very little if any, dependence on particle species and beam energy. The results, when compared to similar LHC measurements, viscous hydrodynamic calculations, and T$\mathrel{\protect\raisebox{-2.1pt}{R}}$ENTo model eccentricities, indicate that initial-state-driven fluctuations predominate the flow fluctuations generated in the collisions studied.
Elliptic flow measurements from two-, four- and six-particle correlations are used to investigate flow fluctuations in collisions of U+U at sNN−−−√ = 193 GeV, Cu+Au at sNN−−−√ = 200 GeV and Au+Au spanning the range sNN−−−√ = 11.5 - 200 GeV. The measurements show a strong dependence of the flow fluctuations on collision centrality, a modest dependence on system size, and very little if any, dependence on particle species and beam energy. The results, when compared to similar LHC measurements, viscous hydrodynamic calculations, and Glauber model eccentricities, indicate that initial-state-driven fluctuations predominate the flow fluctuations generated in the collisions studied.
Azimuthal anisotropy measurement of (multi-)strange hadrons in Au+Au collisions at √sNN = 54.4 GeV
(2023)
Azimuthal anisotropy of produced particles is one of the most important observables used to access the collective properties of the expanding medium created in relativistic heavy-ion collisions. In this paper, we present second (v2) and third (v3) order azimuthal anisotropies of K0S, ϕ, Λ, Ξ and Ω at mid-rapidity (|y|<1) in Au+Au collisions at sNN−−−√ = 54.4 GeV measured by the STAR detector. The v2 and v3 are measured as a function of transverse momentum and centrality. Their energy dependence is also studied. v3 is found to be more sensitive to the change in the center-of-mass energy than v2. Scaling by constituent quark number is found to hold for v2 within 10%. This observation could be evidence for the development of partonic collectivity in 54.4 GeV Au+Au collisions. Differences in v2 and v3 between baryons and anti-baryons are presented, and ratios of v3/v3/22 are studied and motivated by hydrodynamical calculations. The ratio of v2 of ϕ mesons to that of anti-protons (v2(ϕ)/v2(p¯)) shows centrality dependence at low transverse momentum, presumably resulting from the larger effects from hadronic interactions on anti-proton v2.
Purpose: While more advanced COVID-19 necessitates medical interventions and hospitalization, patients with mild COVID-19 do not require this. Identifying patients at risk of progressing to advanced COVID-19 might guide treatment decisions, particularly for better prioritizing patients in need for hospitalization.
Methods: We developed a machine learning-based predictor for deriving a clinical score identifying patients with asymptomatic/mild COVID-19 at risk of progressing to advanced COVID-19. Clinical data from SARS-CoV-2 positive patients from the multicenter Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS) were used for discovery (2020-03-16 to 2020-07-14) and validation (data from 2020-07-15 to 2021-02-16).
Results: The LEOSS dataset contains 473 baseline patient parameters measured at the first patient contact. After training the predictor model on a training dataset comprising 1233 patients, 20 of the 473 parameters were selected for the predictor model. From the predictor model, we delineated a composite predictive score (SACOV-19, Score for the prediction of an Advanced stage of COVID-19) with eleven variables. In the validation cohort (n = 2264 patients), we observed good prediction performance with an area under the curve (AUC) of 0.73 ± 0.01. Besides temperature, age, body mass index and smoking habit, variables indicating pulmonary involvement (respiration rate, oxygen saturation, dyspnea), inflammation (CRP, LDH, lymphocyte counts), and acute kidney injury at diagnosis were identified. For better interpretability, the predictor was translated into a web interface.
Conclusion: We present a machine learning-based predictor model and a clinical score for identifying patients at risk of developing advanced COVID-19.
(1) Background: The aim of our study was to identify specific risk factors for fatal outcome in critically ill COVID-19 patients. (2) Methods: Our data set consisted of 840 patients enclosed in the LEOSS registry. Using lasso regression for variable selection, a multifactorial logistic regression model was fitted to the response variable survival. Specific risk factors and their odds ratios were derived. A nomogram was developed as a graphical representation of the model. (3) Results: 14 variables were identified as independent factors contributing to the risk of death for critically ill COVID-19 patients: age (OR 1.08, CI 1.06–1.10), cardiovascular disease (OR 1.64, CI 1.06–2.55), pulmonary disease (OR 1.87, CI 1.16–3.03), baseline Statin treatment (0.54, CI 0.33–0.87), oxygen saturation (unit = 1%, OR 0.94, CI 0.92–0.96), leukocytes (unit 1000/μL, OR 1.04, CI 1.01–1.07), lymphocytes (unit 100/μL, OR 0.96, CI 0.94–0.99), platelets (unit 100,000/μL, OR 0.70, CI 0.62–0.80), procalcitonin (unit ng/mL, OR 1.11, CI 1.05–1.18), kidney failure (OR 1.68, CI 1.05–2.70), congestive heart failure (OR 2.62, CI 1.11–6.21), severe liver failure (OR 4.93, CI 1.94–12.52), and a quick SOFA score of 3 (OR 1.78, CI 1.14–2.78). The nomogram graphically displays the importance of these 14 factors for mortality. (4) Conclusions: There are risk factors that are specific to the subpopulation of critically ill COVID-19 patients.
The stimulation of the AMP-activated kinase (AMPK) by 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) has been associated with antihyperalgesia and the inhibition of nociceptive signaling in the spinal cord in models of paw inflammation. The attenuated nociception comes along with a strongly reduced paw edema, indicating that peripheral antiinflammatory mechanisms contribute to antinociception. In this study, we investigated the impact of AICAR on the immune cell composition in inflamed paws, as well as the regulation of inflammatory and resolving markers in macrophages. By using fluorescence-activated cell sorting (FACS) analysis and immunofluorescence, we found a significantly increased fraction of proresolving M2 macrophages and anti-inflammatory interleukin (IL)-10 in inflamed tissue, while M1 macrophages and proinflammatory cytokines such as IL-1 were decreased by AICAR in wild type mice. In AMPKα2 knock-out mice, the M2 polarization of macrophages in the paw was missing. The results were supported by experiments in primary macrophage cultures which also showed a shift to a proresolving phenotype with decreased levels of proinflammatory mediators and increased levels of antiinflammatory mediators. However, in the cell cultures, we did not observe differences between the AMPKα2+/+ and −/− cells, thus indicating that the AICAR-induced effects are at least partially AMPK-independent. In summary, our results indicate that AICAR has potent antiinflammatory and proresolving properties in inflammation which are contributing to a reduction of inflammatory edema and antinociception.
We present the first measurement of the proton–Ω correlation function in heavy-ion collisions for the central (0–40%) and peripheral (40–80%) Au + Au collisions at √sNN = 200 GeV by the STAR experiment at the Relativistic Heavy-Ion Collider (RHIC). Predictions for the ratio of peripheral collisions to central collisions for the proton–Ω correlation function are sensitive to the presence of a nucleon– bound state. These predictions are based on the proton– interaction extracted from (2 + 1)-flavor lattice QCD calculations at the physical point. The measured ratio of the proton–Ω correlation function between the peripheral (small system) and central (large system) collisions is less than unity for relative momentum smaller than 40 MeV/c. Comparison of our measured correlation ratio with theoretical calculation slightly favors a proton– bound system with a binding energy of ∼ 27 MeV.
Simple Summary: The introduction of BRAF/MEK-directed targeted therapy (TT) has significantly improved the management of patients with advanced BRAF-V600-mutant melanoma. Although resistance occurs, there is a subgroup of patients showing a complete response (CR) to TT and who maintain durable disease control. For these patients with durable CR, it is not clear whether it is safe to cease therapy. In this retrospective, multicenter study we have analyzed 37 patients who received TT and achieved a CR upon treatment. We identified 15 patients with a durable CR to TT. Overall, patients who discontinued TT (n = 26) were at higher risk of tumor progression compared to patients receiving ongoing TT. Sustained CR was however not restricted to patients with ongoing TT (n = 11) but was also found in patients who ceased TT (n = 4). Finally, our analysis indicated which patients with an initial CR might be most likely to maintain durable CR upon discontinuation of TT.
Abstract: The advent of BRAF/MEK inhibitors (BRAFi/MEKi) has significantly improved progression-free (PFS) and overall survival (OS) for patients with advanced BRAF-V600-mutant melanoma. Long-term survivors have been identified particularly among patients with a complete response (CR) to BRAF/MEK-directed targeted therapy (TT). However, it remains unclear which patients who achieved a CR maintain a durable response and whether treatment cessation might be a safe option in these patients. Therefore, this study investigated the impact of treatment cessation on the clinical course of patients with a CR upon BRAF/MEK-directed-TT. We retrospectively selected patients with BRAF-V600-mutant advanced non-resectable melanoma who had been treated with BRAFi ± MEKi therapy and achieved a CR upon treatment out of the multicentric skin cancer registry ADOReg. Data on baseline patient characteristics, duration of TT, treatment cessation, tumor progression (TP) and response to second-line treatments were collected and analyzed. Of 461 patients who received BRAF/MEK-directed TT 37 achieved a CR. TP after initial CR was observed in 22 patients (60%) mainly affecting patients who discontinued TT (n = 22/26), whereas all patients with ongoing TT (n = 11) maintained their CR. Accordingly, patients who discontinued TT had a higher risk of TP compared to patients with ongoing treatment (p < 0.001). However, our data also show that patients who received TT for more than 16 months and who discontinued TT for other reasons than TP or toxicity did not have a shorter PFS compared to patients with ongoing treatment. Response rates to second-line treatment being initiated in 21 patients, varied between 27% for immune-checkpoint inhibitors (ICI) and 60% for BRAFi/MEKi rechallenge. In summary, we identified a considerable number of patients who achieved a CR upon BRAF/MEK-directed TT in this contemporary real-world cohort of patients with BRAF-V600-mutant melanoma. Sustained PFS was not restricted to ongoing TT but was also found in patients who discontinued TT.
We present a measurement of inclusive J /ψ production at mid-rapidity (|y| < 1) in p+p collisions at a center-of-mass energy of √s = 200 GeV with the STAR experiment at the Relativistic Heavy Ion Collider (RHIC). The differential production cross section for J /ψ as a function of transverse momentum (p T ) for 0 < p T < 14 GeV/c and the total cross section are reported and compared to calculations from the color evaporation model and the non-relativistic Quantum Chromodynamics model. The dependence of J /ψ relative yields in three p T intervals on charged-particle multiplicity at mid-rapidity is measured for the first time in p+p collisions at √s = 200 GeV and compared with that measured at √s = 7 TeV, PYTHIA8 and EPOS3 Monte Carlo generators, and the Percolation model prediction.